Ionis Pharmaceuticals is trading 4.1% down at $44.84 as investors continue reassessing pelacarsen’s commercial and pipeline impact after its failed Phase 3 cardiovascular-outcomes trial.
- Novartis said on September 4 that the study did not meet its primary endpoint, despite lowering Lp(a) levels.
- The decline comes as XBI rises 2.55%, suggesting a company-specific overhang rather than broad risk-off trading.
- No new September 18 company announcement was identified.